Open Access Review Article Article ID: JCMC-7-238

    Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2

    Didar Yanardag Acik*

    In COVID-19, hypertension, diabetes mellitus, coronary artery disease, and immunosuppression are comorbid conditions most often associated with poor prognosis. Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers are widely used in the treatment of these diseases. Therefore, scientists turned their attention to these drugs and brought up the question of whether angiotensin converting enzyme inhibitors and angiotensin receptor blockers may be drugs that adversely affect prognosis in SARS-CoV-2 infection. The authors generally discussed the role of these drugs in SARS-CoV-2 infection through the same mechanisms. We also investigated the effects of these drugs on the immune system.


    Published on: Jul 2, 2020 Pages: 203-206

    Full Text PDF Full Text HTML DOI: 10.17352/2455-2976.000138
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JCMC

    Help ? Google Reviews 11